You can buy or sell Immatics and other stocks, options, ETFs, and crypto commission-free!
Immatics N.V. Ordinary Shares, also called Immatics, is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Read More Its clinical pipelines include adoptive cell therapy (ACT) and TCR biscpecifics (TCER™). Its therapeutic approaches are ACTengine, Next Generation ACT, and TCER. The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.
Tuebingen, Baden Wuerttemberg
52 Week High
52 Week Low